Q-omics provides the consensus-scored ANO9 profile across patient tissues and cancer cell-line models. ANO9 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ANO9 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ANO9 RNA expression shows 15,425 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight OV, COAD, and LIHC as cancer lineages where ANO9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANO9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANO9 survival associations across molecular data types. ANO9 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANO9 RNA expression–survival associations across cancer types. High ANO9 expression shows unfavorable associations in OV, LGG and UVM, but favorable associations in BLCA, SKCM and MESO. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify OV as the clearest survival context for ANO9 RNA expression.
This table summarizes ANO9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ANO9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANO9 shows higher tumor expression in COAD, STAD, LUAD, UCEC, BLCA and BRCA. The COAD box plot shows higher ANO9 RNA expression in tumor versus normal tissue (log2 FC = +1.396, t-test p < 0.001).
This table shows molecular features associated with ANO9 in patient tissues and cancer cell lines. In patient samples, ANO9 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANO9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
